Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

A duo of experts from Weill Cornell Medicine talked about the advancements made in diffuse midline gliomas research and clinical trials that may offer new hope for improving its historically poor prognosis.

A Changing Clinical Landscape: Promising Therapeutic Avenues in the Treatment of DIPG and Other Diffuse Midline Gliomas

Videos

The professor of pediatrics and division chief of Medical Genetics at Duke University gave clinical insight on a presentation on the advancements and limitations of enzyme replacement therapy for Pompe Disease. [WATCH TIME: 3 minutes]

Celebrating Milestones and Tackling New Frontiers in Pompe Disease: Priya Kishnani, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert Califf, MD. [LISTEN TIME: 9 minutes]

Episode 137: Advancing Neuromuscular Care and Research

Marketed as Amvuttra, the Alnylam Pharmaceuticals RNA-interference treatment is now approved for an additional patient population of 150,000 in the US, and more than 300,000 worldwide.

FDA Approves Vutrisiran for ATTR-CM, Expanding Indication in Amyloidosis

Associate professor of neurological sciences and chief of the Multiple Sclerosis Division at the University of Vermont in Burlington.

The professor of neurological sciences at the University of Vermont discussed the work of the MS Differential Diagnosis Consortium, highlighting efforts to refine MS differential diagnosis and improve clinical accuracy. [WATCH TIME: 8 minutes]

Updates on Guidance for Diagnosing Pediatric and Late-Onset Multiple Sclerosis: Andrew Solomon, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The MyacarinG study post-hoc analysis demonstrated rozanolixizumab's potential to significantly reduce ocular symptoms in gMG, with consistent improvements across multiple scoring systems.

Ocular Symptoms of Myasthenia Gravis Improved With Rozanolixizumab

Kathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.

Continuing the Vision of June Halper: What's Next for CMSC

Interim chief executive officer of the Consortium of Multiple Sclerosis Centers.

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

What to Expect From the 2025 CMSC Annual Meeting: Kathleen Costello, CRNP, MSCN

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Cure SMA

SAP Partners

Episode 1: Overview of Telehealth in Clinical Practice and Patient Options

Episode 2: How Telehealth Can Improve Care for Patients With SMA

Episode 3: Utilizing Telehealth to Conduct Multidisciplinary Visits in SMA Care

Episode 4: The Limitations of Telehealth for Treating SMA

Episode 5: The COVID-19 Pandemic's Effect on Telehealth Use for SMA

Episode 6: Easing the Process of Learning to Use, Incorporate Telehealth in Practice

Episode 7: Prepping Patients With SMA and Their Families Prior to Telehealth Visits

Episode 8: Proposed Solutions to the Limitations of Telehealth

Episode 9: Maximizing Patient Engagement During Telehealth Visits

Episode 10: How Telehealth Provides Insight, Perspective on At-Home Challenges

Episode 11: Resources Available for Patients With SMA 

Cure SMA is dedicated to the treatment and care of spinal muscular atrophy (SMA). Since 1984, Cure SMA has grown to be the largest network of individuals, families, clinicians, and research scientists working together to advance SMA research, support the full SMA community, and educate the public and professional communities about SMA. The organization has directed and invested in comprehensive research that has shaped the scientific community's understanding of SMA, led to breakthroughs in treatment and care, and provides individuals and families the support they need today. For more information, visit 

SAP Partner

Clinical

Lessons Learned in Telehealth When Implementing Multidisciplinary Care for Patients Affected by SMA